|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.680 NZD | +0.27% |
|
+0.82% | +8.88% |
| 06-24 | NZX Biggest Gainers | MT |
| 06-24 | AFT Pharmaceuticals Gets US FDA Nod for Phase 3 Trial of Injectable Iron Therapy | MT |
| Market Cap | 386M 218M 191M 176M 165M 309M 20.57B 316M 2.12B 819M 10.16B 819M 801M 35.24B | P/E 2027 * |
19.6x | P/E 2028 * | 15.5x |
|---|---|---|---|---|---|
| Enterprise Value | 416M 235M 206M 190M 178M 333M 22.16B 340M 2.28B 883M 10.95B 882M 863M 37.97B | EV / Sales 2027 * |
1.37x | EV / Sales 2028 * | 1.19x |
| Free-Float |
22.37% | Yield 2027 * |
0.89% | Yield 2028 * | 1.13% |
Last Transcript: AFT Pharmaceuticals Limited
| 20/01/24 | Rentevrees zet Bel20 onder druk | |
| 19/01/24 | KBC uitblinker op groene beurs | |
| 19/01/24 | Brusselse beurs opent flink hoger | |
| 19/01/24 | Brussel start handelsdag vermoedelijk in het groen | |
| 18/01/24 | Hyloris gaat samenwerken met AFT Pharmaceuticals |
| 1 day | +0.27% | ||
| 1 week | +0.82% | ||
| Current month | -6.36% | ||
| 1 month | -5.15% | ||
| 3 months | +8.24% | ||
| 6 months | +5.14% | ||
| Current year | +8.88% |
| 1 week | 3.66 |  | 3.8 |
| 1 month | 3.65 | | 3.98 |
| Current year | 3.35 | | 3.98 |
| 1 year | 2.54 | | 3.98 |
| 3 years | 2.37 | | 3.98 |
| 5 years | 2.37 | | 5 |
| 10 years | 1.7 | | 5.65 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marree Atkinson
HRO | Human Resources Officer | - | 04/09/2012 |
Hartley Atkinson
CEO | Chief Executive Officer | - | 04/09/1997 |
Stuart Houliston
DFI | Director of Finance/CFO | - | 15/06/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
David Flacks
CHM | Chairman | - | 22/06/2015 |
Hartley Atkinson
BRD | Director/Board Member | - | 04/09/1997 |
Marree Atkinson
BRD | Director/Board Member | - | 04/09/2012 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 03/07/25 | Buy | Founder | 200,000 | 0.1907% | ||
| 26/06/25 | Free | Founder | 17,755 | 0.0169% | ||
| 02/12/24 | Buy | Founder | 45 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.27% | +0.82% | +43.75% | +0.82% | 218M | |
| +7.13% | +9.97% | +51.94% | +166.83% | 1,077B | |
| +3.99% | +11.50% | +67.53% | +55.63% | 613B | |
| +4.20% | +17.03% | +35.63% | +87.74% | 448B | |
| +0.99% | +4.85% | +27.93% | +22.82% | 332B | |
| +1.82% | +8.19% | +41.15% | +26.80% | 293B | |
| +0.22% | +6.75% | +31.51% | +42.02% | 286B | |
| +0.73% | +8.53% | -26.22% | -40.85% | 215B | |
| +1.56% | +6.14% | +28.38% | +59.45% | 193B | |
| +3.26% | +3.33% | +18.83% | +67.03% | 159B | |
| Average | +1.89% | +7.20% | +32.04% | +48.83% | 361.63B | |
| Weighted average by Cap. | +2.26% | +8.93% | +40.51% | +81.28% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 304M 172M 151M 139M 130M 244M 16.19B 249M 1.67B 645M 8B 645M 631M 27.75B | 345M 195M 171M 158M 148M 277M 18.4B 283M 1.9B 733M 9.1B 733M 717M 31.54B |
| Net income | 19.71M 11.13M 9.76M 9M 8.43M 15.8M 1.05B 16.13M 108M 41.85M 519M 41.81M 40.9M 1.8B | 24.84M 14.03M 12.3M 11.34M 10.62M 19.91M 1.32B 20.32M 136M 52.74M 654M 52.69M 51.54M 2.27B |
| Net Debt | 29.84M 16.86M 14.78M 13.62M 12.76M 23.92M 1.59B 24.41M 164M 63.36M 786M 63.3M 61.92M 2.73B | 24.59M 13.89M 12.18M 11.23M 10.51M 19.71M 1.31B 20.12M 135M 52.21M 648M 52.16M 51.02M 2.25B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/06/26 | NZ$3.680 | +0.27% | 7,997 |
| 25/06/26 | NZ$3.670 | -2.13% | 12,778 |
| 24/06/26 | NZ$3.750 | +0.81% | 10,615 |
| 23/06/26 | NZ$3.720 | +1.09% | 3,455 |
| 22/06/26 | NZ$3.680 | +0.82% | 82,462 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- AFT Stock
Select your edition
All financial news and data tailored to specific country editions
